About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/24/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/24/2020.
  • T-Cell Engagers

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Investigational T-cell engager (TCE) therapies utilize antibodies engineered to contain multiple binding domains, designed to specifically and simultaneously recognize T cells and antigen-expressing target cells.1,2 This dual binding brings the two cells in close proximity, facilitating cross-linking, which is proposed to result in T-cell activation and cytokine release, followed by cytolytic synapse formation, secretion of cytolytic enzymes, and subsequent cell death.1,2 Surface antigen binding domains, such as B-cell maturation antigen (BCMA) domains, allow for targeting with specific affinity for BCMA-expressing cells, including multiple myeloma cells.1,2 A T-cell binding domain, such as a CD3 domain, allows for specific targeting of T cells and their subsequent activation.1 Autoimmunity is potentially decreased by silencing the Fc region of TCE antibodies, to potentially reduce interactions with innate immune cells and reduce antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) induction.1-3 The silenced Fc region retains immunoglobulin-like pharmacokinetic properties and the capacity to bind to FcRn.3,5 Preclinical studies suggest that TCEs bypass the immune system’s need for antigen presentation by the major histocompatibility complex (MHC) and can directly target antigen-expressing cells.1,4Preclinical studies of the benefits and risks of TCEs are ongoing, including development of an investigational anti-BCMA 2 + 1 TCE for treatment of relapsed/refractory multiple myeloma.1,2,5

    View Related Molecules

    References

    1. Seckinger A, et al. Cancer Cell. 2017;31:396-410. PMID: 28262554
    2. Vu MD, et al. Blood. 2015;126:2998.
    3. Schlothauer T, et al. Protein Eng Des Sel. 2016;29:457-466. PMID: 27578889
    4. Slaney CY, et al. Cancer Discov. 2018;8:924-934. PMID: 30012854
    5. Klein C, et al. Poster Presented at AARC 2017 [abstract 3629].